Course and treatment of diabetes mellitus in the context of COVID-19

In 2020, the world is facing a historically unparalleled public health challenge associated with the invasion of the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This is also a challenge for the healthcare systems worldwide. Patients with diabetes mellitus (DM) are most vulnerab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina V. Shestakova, Natalya G. Mokrysheva, Ivan I. Dedov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	coronavirus covid-19 diabetes mellitus type 2 angiotensin-converting enzyme glucocorticoids Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/9e32dd94b4b841ed9cde0bd39372fe5b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e32dd94b4b841ed9cde0bd39372fe5b
record_format	dspace
spelling	oai:doaj.org-article:9e32dd94b4b841ed9cde0bd39372fe5b2021-11-14T09:00:23ZCourse and treatment of diabetes mellitus in the context of COVID-192072-03512072-037810.14341/DM12418https://doaj.org/article/9e32dd94b4b841ed9cde0bd39372fe5b2020-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12418https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378In 2020, the world is facing a historically unparalleled public health challenge associated with the invasion of the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This is also a challenge for the healthcare systems worldwide. Patients with diabetes mellitus (DM) are most vulnerable to COVID-19 because of the peculiarities of their immune response to a virus attack and due to their high susceptibility to viral activity because of hyperglycemia and other comorbid conditions and obesity that often accompany DM. The severity of the COVID-19 disease requires a mandatory review of the usual anti-hyperglycemic therapy. Maintaining optimal glycemic control and preventing the development of ketoacidosis remain extremely important; therefore, insulin becomes the priority drug for glycemic control in most cases. The search for new drugs to fight against the coronavirus infection continues with new randomised clinical drug trials being launched. Innovative anti-diabetic agents are also being tested as candidates for potentially effective anti-coronavirus agents.Marina V. ShestakovaNatalya G. MokryshevaIvan I. DedovEndocrinology Research Centrearticlecoronaviruscovid-19diabetes mellitustype 2 angiotensin-converting enzymeglucocorticoidsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 2, Pp 132-139 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	coronavirus covid-19 diabetes mellitus type 2 angiotensin-converting enzyme glucocorticoids Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	coronavirus covid-19 diabetes mellitus type 2 angiotensin-converting enzyme glucocorticoids Nutritional diseases. Deficiency diseases RC620-627 Marina V. Shestakova Natalya G. Mokrysheva Ivan I. Dedov Course and treatment of diabetes mellitus in the context of COVID-19
description	In 2020, the world is facing a historically unparalleled public health challenge associated with the invasion of the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This is also a challenge for the healthcare systems worldwide. Patients with diabetes mellitus (DM) are most vulnerable to COVID-19 because of the peculiarities of their immune response to a virus attack and due to their high susceptibility to viral activity because of hyperglycemia and other comorbid conditions and obesity that often accompany DM. The severity of the COVID-19 disease requires a mandatory review of the usual anti-hyperglycemic therapy. Maintaining optimal glycemic control and preventing the development of ketoacidosis remain extremely important; therefore, insulin becomes the priority drug for glycemic control in most cases. The search for new drugs to fight against the coronavirus infection continues with new randomised clinical drug trials being launched. Innovative anti-diabetic agents are also being tested as candidates for potentially effective anti-coronavirus agents.
format	article
author	Marina V. Shestakova Natalya G. Mokrysheva Ivan I. Dedov
author_facet	Marina V. Shestakova Natalya G. Mokrysheva Ivan I. Dedov
author_sort	Marina V. Shestakova
title	Course and treatment of diabetes mellitus in the context of COVID-19
title_short	Course and treatment of diabetes mellitus in the context of COVID-19
title_full	Course and treatment of diabetes mellitus in the context of COVID-19
title_fullStr	Course and treatment of diabetes mellitus in the context of COVID-19
title_full_unstemmed	Course and treatment of diabetes mellitus in the context of COVID-19
title_sort	course and treatment of diabetes mellitus in the context of covid-19
publisher	Endocrinology Research Centre
publishDate	2020
url	https://doaj.org/article/9e32dd94b4b841ed9cde0bd39372fe5b
work_keys_str_mv	AT marinavshestakova courseandtreatmentofdiabetesmellitusinthecontextofcovid19 AT natalyagmokrysheva courseandtreatmentofdiabetesmellitusinthecontextofcovid19 AT ivanidedov courseandtreatmentofdiabetesmellitusinthecontextofcovid19
_version_	1718429479433404416

Course and treatment of diabetes mellitus in the context of COVID-19

Ejemplares similares